What are the key benefits and risks of co-investments alongside PE funds, and how should LPs structure their co-investment governance?

Co-investments allow Limited Partners to invest directly in specific deals alongside a GP's main fund, typically at reduced or zero management fees and carried interest. While fee savings can be substantial (200-400 bps annually versus fund economics), co-investments introduce adverse selection risk, capacity constraints, and governance challenges that require dedicated in-house capabilities.\n\nCo-Investment Economics:\n\n`mermaid\ngraph TD\n A[\"GP identifies $500M deal\"] --> B[\"Fund invests $300M
(within concentration limit)\"]\n A --> C[\"GP offers $200M co-invest
to select LPs\"]\n C --> D[\"LP Co-Invest Terms\"]\n D --> E[\"Management fee: 0%
(vs. 2% in fund)\"]\n D --> F[\"Carry: 0-10%
(vs. 20% in fund)\"]\n D --> G[\"No J-curve delay
Capital deployed immediately\"]\n E --> H[\"Fee savings on $200M
over 5-year hold:
$20M+ in saved fees\"]\n`\n\nBenefits for LPs:\n\n| Benefit | Quantification |\n|---|---|\n| Fee reduction | 150-400 bps annually vs. fund terms |\n| Portfolio construction control | Choose specific sectors, geographies, deal sizes |\n| Increased PE exposure | Deploy more capital without increasing GP count |\n| Faster capital deployment | No blind pool waiting period |\n| Greater transparency | Full deal-level visibility |\n| GP relationship deepening | Preferred access to future co-invest and next fund |\n\nAdverse Selection Risk -- The Critical Concern:\n\nGPs may preferentially offer co-investments on deals where:\n1. The deal is too large for the fund's concentration limits (legitimate)\n2. The GP is less confident in the outcome (adverse selection)\n3. The GP wants to reduce its own risk on a specific deal (misalignment)\n4. The deal has lower expected returns than the fund average (cherry-picking the other way)\n\nWorked Example -- Ironwood Pension Co-Investment Program:\n\nIronwood receives a co-investment offer from Thornfield Equity Partners for a $420M acquisition of Meridian Healthcare Services:\n\n| Parameter | Detail |\n|---|---|\n| Total deal equity | $420M |\n| Fund allocation | $280M (Thornfield Fund VI, $2B fund) |\n| Co-invest offered | $140M (split among 3 LPs) |\n| Ironwood allocation | $50M |\n| Co-invest fees | 0% management fee, 10% carry over 8% hurdle |\n| Decision timeline | 10 business days from term sheet |\n\nIronwood's Evaluation Process (Compressed Timeline):\n\nDay 1-2: Receive information memorandum, financial model, management presentations\nDay 3-5: Independent due diligence\n- Validate revenue assumptions against industry data\n- Review customer concentration (top 5 customers = 35%)\n- Assess management team (CEO since founding, CFO recruited 18 months ago)\n- Compare entry multiple (9.5x EBITDA) to comparable transactions\n\nDay 6-7: Investment committee review\n- Stress test downside scenarios\n- Assess fit with existing healthcare exposure in portfolio\n- Evaluate GP's track record in healthcare (3 prior deals: 2.8x, 1.9x, 2.3x multiples)\n\nDay 8: Investment committee decision\n\nGovernance Framework for Co-Investments:\n\n| Element | Blind Pool Fund | Co-Investment |\n|---|---|---|\n| Decision maker | GP (delegated authority) | LP investment committee |\n| Due diligence timeline | N/A (GP manages) | 5-15 business days |\n| In-house team required | Monitoring only | Sourcing, underwriting, legal |\n| Legal counsel | Fund LPA (pre-agreed) | Deal-specific co-invest agreement |\n| Ongoing monitoring | GP reports quarterly | LP must independently monitor |\n| Exit decision | GP controls timing | Co-invest typically follows fund exit |\n| Minimum LP AUM for program | $500M+ in PE | $2B+ (realistically) |\n\nCommon Pitfalls:\n1. Speed pressure: GPs set tight deadlines, preventing thorough DD\n2. Relationship bias: LPs approve weak deals to maintain GP relationship\n3. Concentration risk: Co-investments can create sector/geography overweight\n4. Denominator effect: Large co-investments amplify PE allocation during market downturns\n5. Governance mismatch: LP has no board seat or control rights in the portfolio company\n\nExplore co-investment program design in our CFA Level III course materials.